五月 2026
ane.pl
显示 Similarweb 估计数据。
关联 GA4,公开验证您的网站指标
与您的成功同步
绑定 Google Analytics,验证您网站的流量及用户参与度指标
跳出率
39.64%
每次访问页数
2.06
平均访问时长
00:00:47
- 公司
- - -
- 行业
- - -
ane.pl的 10 大竞争对手
在 五月 2026 与 ane.pl 相似的前 10 名网站,按关键字流量、受众定位和市场重叠方面与 ane.pl 的关联性排名
- 公司
- - -
- 行业
- - -
跳出率
40.33%
每次访问页数
1.69
平均访问时长
00:00:20
Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
64.63%
每次访问页数
1.91
平均访问时长
00:01:41
Dr. Mikhail Blagosklonny | Aging
- 公司
- - -
- 行业
- - -
跳出率
43.92%
每次访问页数
1.69
平均访问时长
00:00:50
跳出率
44.41%
每次访问页数
1.56
平均访问时长
00:00:14
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
- -
每次访问页数
- -
平均访问时长
- -
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
- -
每次访问页数
- -
平均访问时长
- -
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
79.68%
每次访问页数
1.12
平均访问时长
00:00:03
the scientific journal acta scientiarum polonorum. oeconomia began publication in 2001. it was established and operates under the aegis of a consortium of polish agricultural universities.
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
28.73%
每次访问页数
1.93
平均访问时长
00:00:13
跳出率
51.63%
每次访问页数
2.49
平均访问时长
00:01:40
Got questions about running the 2027 TCS London Marathon for the National Autistic Society? Find answers on places, fundraising, training support and more.
跳出率
57.4%
每次访问页数
2.14
平均访问时长
00:01:33
ane.pl在 五月 2026 的前五名竞争对手是:cellmolbiol.org、jnm.snmjournals.org、aging-us.com、remedypublications.com等。
根据 Similarweb 的月访问量数据,ane.pl 在 五月 2026 的头号竞争对手是 cellmolbiol.org。与 ane.pl 相似度排名第二的网站是 jnm.snmjournals.org,排名第三的是 aging-us.com。
在 五月 2026,remedypublications.com 被评为与 ane.pl 相似度第四高的网站,klab.tch.harvard.edu 位居第五。
进入前十名榜单的其他五家竞争对手分别是 onlinebooks.library.upenn.edu、repec.iza.org、aspe.sggw.edu.pl、college-de-france.fr 和 autism.org.uk。
